PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents growing 2.36% while AXSM's declined -4.76%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Below half of AXSM's -4.76%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Above 1.5x AXSM's -1.86%. Michael Burry might investigate for potential short-term asset misclassification or risk.
1.99%
≥ 1.5x AXSM's 0.55%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.06%
Below half AXSM's -29.26%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AXSM and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
≥ 1.5x AXSM's -0.05%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
1.71%
≥ 1.5x AXSM's 0.46%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
22.15%
Above 1.5x AXSM's 14.03%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Similar yoy growth to AXSM's -100.00%. Walter Schloss notes parallel approach to deferred revenue.
No Data
No Data available this quarter, please select a different quarter.
20.63%
50-75% of AXSM's 29.52%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of AXSM's 0.45%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Less than half of AXSM's 10.87%. David Dodd sees far fewer liability expansions relative to competitor.
6.90%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
-3.28%
Below half AXSM's -8.78%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Less than half of AXSM's 200.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AXSM's zero value, indicating worse performance.
-0.05%
Below half AXSM's -28.59%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
≥ 1.5x AXSM's 0.46%. David Dodd sees faster overall balance sheet growth than competitor.
0.63%
Higher Total Investments Growth compared to AXSM's zero value, indicating better performance.
-6.71%
Less than half of AXSM's 1.25%. David Dodd sees less overall debt expansion vs. competitor.
-2.57%
Less than half of AXSM's 12.78%. David Dodd sees better deleveraging or stronger cash buildup than competitor.